New antibiotics in the treatment of urinary tract infections




urinary tract infections, europe, resistance, antibiotics


Antibiotics are very often prescribed for the indication urinary tract infections (UTIs). Therefore, UTIs are an important field for the development of antibiotic resistance. A number of new antibiotics have been tested for the indication complicated UTI / pyelonephritis. These are cephalosporins and carbapenems, in combination with new beta-lactamase inhibitors, cefiderocol as a new type of cephalosporin, plazomicin a new aminoglycoside, eravacycline a new tetracycline, and intravenous fosfomycin. Not all antibiotics are approved in Europe. Although the development of these new substances is promising, these new antibiotics should be used very carefully to avoid the development of new antibiotic resistance against these new substances.


Wagenlehner F.M.E., Bjerklund J.T.E., Cai T., Koves B., Kranz J., Pilatz A., et al. Epidemiology, definition and treatment of complicated urinary tract infections. Nat Rev Urol. 2020. Vol. 17, No. 10. P. 586–600.

Wagenlehner F.M., Umeh O., Steenbergen J., Yuan G., Darouiche R.O. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015. Vol. 385, No. 9981. P. 1949–1956.

Wagenlehner F.M., Sobel J.D., Newell P., Armstrong J., Huang X., Stone G.G. et al. Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clin Infect Dis. 2016. Vol. 63, No. 6. P. 754–762.

Malaisri C., Phuphuakrat A., Wibulpolprasert A., Santanirand P., Kiertiburanakul S. A randomized controlled trial of sitafloxacin vs. ertapenem as a switch therapy after treatment for acute pyelonephritis caused by extended-spectrum beta-lactamase-producing Escherichia coli: A pilot study. J Infect Chemother. 2017. Vol. 23, No. 8. P. 556–562.

Seo Y.B., Lee J., Kim Y.K., Lee S.S., Lee J.A., Kim H.Y. et al. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli. BMC Infect Dis. 2017. Vol. 17, No. 1. P. 404.

Sims M., Mariyanovski V., McLeroth P., Akers W., Lee Y.C., Brown M.L. et al. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother. 2017. Vol. 72, No. 9. P. 2616–2626.

Kaye K.S., Bhowmick T., Metallidis S., Bleasdale S.C., Sagan O.S., Stus V. et al. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. JAMA. 2018. Vol. 319, No. 8. P. 788–799.

Portsmouth S., van Veenhuyzen D., Echols R., Machida M., Ferreira J.C.A., Ariyasu M. et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018. Vol. 18. No. 12. P. 1319–1328.

Wagenlehner F.M.E., Naber K.G. Cefiderocol for treatment of complicated urinary tract infections. Lancet Infect Dis. 2019. Vol. 19, No. 1. P. 22–23.

Pharmaceuticals T. Tetraphase Announces Top-Line Results from IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract Infections (cUTI). 2018. URL:

Kaye K.S., Rice L.B., Dane A., Stus V., Sagan O., Fedosiuk E. et al. Fosfomycin for injection (ZTI-01) vs Piperacillin-Tazobactam (PIP-TAZ) for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP): ZEUS, A Phase 2/3 Randomized Trial. Clin Infect Dis. 2019.

Wagenlehner F.M.E., Cloutier D.J., Komirenko A.S., Cebrik D.S., Krause K.M., Keepers T.R. et al. Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med. 2019. Vol. 380, No. 8. P. 729–740.